PURE Bioscience to Present at the Aegis Healthcare Conference on September 28

Before you go, we thought you'd like these...
Before you go close icon

PURE Bioscience to Present at the Aegis Healthcare Conference on September 28

SAN DIEGO--(BUSINESS WIRE)-- PURE Bioscience, Inc. (NASDAQ:PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced that Chief Executive Officer Michael L. Krall is schedule to present at the Aegis Capital Healthcare Conference on Friday, September 28, 2012 at 8:00 a.m. Pacific. The conference is being held at The Wynn in Las Vegas.

About Aegis Capital


Founded in 1984, Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital's management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of our clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. Aegis Capital continues to meet the challenging and changing markets by investing in world-class services such as access to independent research for its financial advisors and their clients from JP Morgan, Bloomberg, Moody's, Lipper, Best Independent Research LLC, and Argus Research. Aegis Capital's clients have access to Asset Management Services with world-class managers.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.



Investor Contact:
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article PURE Bioscience to Present at the Aegis Healthcare Conference on September 28 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners